Latham & Watkins Advises Erasca in Upsized US$225 Million Offering of Common Stock

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, has announced the pricing of an upsized public offering of 22,500,000 shares of its common stock. The shares of common stock are being sold to the public at a price of US$10 per share. All of the shares of common stock to be sold in the public offering are to be sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be US$225 million. In addition, Erasca has granted the underwriters a 30-day option to purchase up to an additional 3,375,000 shares of common stock at the offering price, less underwriting discounts and commissions. The offering is expected to close on January 23, 2026, subject to the satisfaction of customary closing conditions.

Latham & Watkins represents Erasca in the offering with a San Diego-based corporate team led by partners Matt Bush and Cheston Larson and counsel Anthony Gostanian, with associates Shelby Harrison and Madeline Hodges.